Recent studies also showed the clinical efficacy of neoadjuvant pyrotinib, trastuzumab, and chemotherapy in HER2‐positive breast cancer, further supporting the feasibility of dual HER2‐targeted regimen.18 The gene discussed is ERBB2; the disease is breast carcinoma.